With standard doublet chemotherapy for patients with advanced non-small-cell lung cancer
(NSCLC), we have reached an outcome plateau of about 10 months median overall survival …

7553 Background: Maintenance therapy is a new treatment paradigm following first-line
combination chemotherapy for patients with advanced non-small cell lung cancer (NSCLC) …

Non-small cell lung cancer (NSCLC) is the leading cause of cancer death in the
industrialized world. Despite significant progress in early stage disease, survival rates for …

Opinion statement The standard of care for the treatment of patients with advanced NSCLC
includes 4-6 cycles of platinum-doublet chemotherapy with or without bevacizumab, with …

Evidence has suggested survival benefits of maintenance for advanced NSCLC patients not
progressing after first‐line chemotherapy. Additionally, particular first‐line targeted therapies …

Maintenance therapy has emerged as a novel therapeutic paradigm for advanced non-small-
cell lung cancer (NSCLC). Maintenance therapy that aims to sustain a clinically favorable …

Maintenance therapy for patients with advanced non-small cell lung cancer has been an
area of intense investigation. Maintenance therapy has been divided into two broad …

Background Prospective studies have implied that maintenance therapy for non-small cell
lung cancer (NSCLC) has its effect by giving active drugs earlier to patients who otherwise …

Several randomized trials have investigated the role of maintenance treatment for patients
with advanced non-small cell lung cancer (NSCLC) not progressed after completion of first …

Background Can single-agent maintenance therapy be considered as an ideal strategy for
non-small cell lung cancer (NSCLC) treatment to achieve prolonged survival and tolerated …